Soru

Investigators recently concluded a Phase III clinical study assessing a new monoclonal antibody against interleukin-5 (IL-5). The trial enrolled adults with severe, uncontrolled eosinophilic asthma to determine the drug's efficacy in preventing disease exacerbations. A total of $2,000$ participants were randomly assigned to receive either the IL-5 inhibitor or a matching placebo. The primary endpoint was the incidence of at least one severe asthma exacerbation requiring an emergency department visit or hospitalization over a $12$-month period.

Data analysis revealed the following:
- Among the $1,200$ participants who received the IL-5 inhibitor, $108$ experienced a severe exacerbation.
- Among the $800$ participants who received the placebo, $112$ experienced a severe exacerbation.

Based on these findings, calculate the number needed to treat (NNT) to prevent one additional severe asthma exacerbation. (Enter your answer as a whole number)